Prime Crude

🕓 Estimated Reading Time: 5 minutes Overview Vivos Therapeutics, Inc. (VVOS), a medical technology company focused on treating patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA), is gearing up for a pivotal financial disclosure. The company is anticipated to announce its latest quarterly VVOS earnings on an upcoming Thursday, as reported by The Markets Daily ( Source ). This highly anticipated report comes at a critical juncture for Vivos, as investors and market observers keenly await insights into its financial health, operational progress, and future growth trajectory. The forthcoming results are expected to provide clarity on the adoption rate of its proprietary Vivos System, its financial performance in a competitive healthcare landscape, and strategic developments shaping its market position. Shareholders and potential investors will be scrutinizing revenue figures, profitability margins, and any updates on clinical trials o...

🕓 Estimated Reading Time: 5 minutes Overview RBC Capital Markets has issued a revised assessment of industrial conglomerate 3M Co. ( 3M stock ), notably increasing its price target while simultaneously reiterating its 'Underperform' rating. This nuanced adjustment reflects a complex interplay of factors affecting the multinational corporation, from ongoing legal liabilities to strategic business divestitures. The bank's analysts have lifted the MMM price target to $130, a significant jump from the previous $108. However, the decision to maintain the 'Underperform' RBC Capital rating signals persistent concerns about the company's risk profile and future performance trajectory, as reported by Insider Monkey. Background & Context 3M, a diversified technology company renowned for its wide array of products ranging from Post-it Notes to industrial abrasives and health care solutions, has been navigating a challenging period marked by significant litigation an...

HSBC Adjusts Accenture Stock Rating to Moderate Sell 🕓 Estimated Reading Time: 5 minutes HSBC Global Research has shifted its outlook on Accenture (NYSE: ACN) shares. The multinational banking giant now rates Accenture stock with a 'moderate sell' recommendation. This adjustment reflects current market dynamics, sector performance, and specific company fundamentals. Investors are keenly observing the implications of this change on Accenture's market position. Overview In a significant move watched closely by the global financial community, HSBC Global Research has recalibrated its stance on Accenture (NYSE: ACN), the leading global professional services company. The firm’s latest assessment sees the Accenture stock rating updated to 'moderate sell.' This adjustment, reported on July 30, 2025, by American Banking News, signals a more cautious outlook on the consulting and IT services giant's near-term share performance. Such revisions from major financial insti...

Jim Cramer's Expert Insights on 17 Key Stocks 🕓 Estimated Reading Time: 5 minutes Jim Cramer recently shared his views on 17 diverse stocks, offering guidance for current market conditions. His commentary spans from high-growth tech firms in the AI sector to traditional utilities and consumer discretionary companies. Cramer continues to emphasize holding strong performers and cautioning against highly speculative or fundamentally weak enterprises. Investors are encouraged to consider his perspectives as part of a broader, well-researched investment strategy. Overview In the dynamic world of financial markets, investment insights from seasoned commentators often grab headlines. Jim Cramer, the outspoken host of CNBC's 'Mad Money,' recently weighed in on a diverse portfolio of 17 individual stocks, offering his candid opinions and advice to investors. His latest commentary, as compiled by Insider Monkey, provides a snapshot of his current market outlook, emphasizing...